Association between left atrial low-voltage area and induction and recurrence of macroreentrant atrial tachycardia in pulmonary vein isolation for atrial fibrillation
Journal of Interventional Cardiac Electrophysiology · 2024
DOI: 10.1007/s10840-024-01760-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Interventional Cardiac Electrophysiology, 2024. Verfasst von Koichiro Sonoda und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Sasebo City General Hospital, 9-3 Hirase-cho, Sasebo, 857-8511, Japan. ksonoq@yahoo.co.jp. Hauptthemen laut MEDLINE: Atrial Fibrillation, Pulmonary Veins, Catheter Ablation, Recurrence. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The relationship between induction and recurrence due to atrial tachycardia (AT) and left atrial (LA) matrix progression after atrial fibrillation (AF) ablation remains unclear.
Methods
One hundred fifty-two consecutive patients with paroxysmal and persistent AF who underwent pulmonary vein isolation (PVI) and cavo-tricuspid isthmus (CTI) ablation and achieved sinus rhythm before the procedure were classified into three groups according to the AT pattern induced after the procedure: group N (non-induced), F (focal pattern), and M (macroreentrant pattern) in 3D mapping.
Results
The total rate of AT induction was 19.7% (30/152) in groups F ( n = 13) and M ( n = 17). Patients in group M were older than those in groups N and F, with higher CHADS 2 /CHA 2 DS 2 -VASc values, left atrial enlargement, and low-voltage area (LVA) size of LA. The receiver operating characteristic curve determined that the cut-off LVA for macroreentrant AT induction was 8.8 cm 2 (area under the curve [AUC]: 0.86, 95% confidence interval [CI]: 0.75–0.97). The recurrence of AT at 36 months in group N was 4.1% (5/122), and at the second ablation, all patients had macroreentrant AT. Patients with AT recurrence in group N had a wide LVA at the first ablation, and the cut-off LVA for AT recurrence was 6.5 cm 2 (AUC 0.94, 95%CI 0.88–0.99). Adjusted multivariate analysis showed that only LVA size was associated with the recurrence of macroreentrant AT (odds ratio 1.21, 95%CI 1.04–1.51).
Conclusions
It is important to develop a therapeutic strategy based on the LVA size to suppress the recurrence of AT in these patients. Graphical abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Sasebo City General Hospital, 9-3 Hirase-cho, Sasebo, 857-8511, Japan. ksonoq@yahoo.co.jp.
- Department of Cardiology, Sasebo City General Hospital, 9-3 Hirase-cho, Sasebo, 857-8511, Japan.
- Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Zitieren
APA
Sonoda, K., Fukushima, T., Takei, A., Otsuka, K., Hata, S., Shinboku, H., Muroya, T., & Maemura, K. (2024). Association between left atrial low-voltage area and induction and recurrence of macroreentrant atrial tachycardia in pulmonary vein isolation for atrial fibrillation. Journal of Interventional Cardiac Electrophysiology. https://doi.org/10.1007/s10840-024-01760-8
Vancouver
Sonoda K, Fukushima T, Takei A, Otsuka K, Hata S, Shinboku H, et al. Association between left atrial low-voltage area and induction and recurrence of macroreentrant atrial tachycardia in pulmonary vein isolation for atrial fibrillation. Journal of Interventional Cardiac Electrophysiology. 2024. doi:10.1007/s10840-024-01760-8
BibTeX
@article{Sonoda2024,
author = {Sonoda, Koichiro and Fukushima, Tadatomo and Takei, Asumi and Otsuka, Kaishi and Hata, Shiro and Shinboku, Hiroki and Muroya, Takahiro and Maemura, Koji},
title = {Association between left atrial low-voltage area and induction and recurrence of macroreentrant atrial tachycardia in pulmonary vein isolation for atrial fibrillation},
journal = {Journal of Interventional Cardiac Electrophysiology},
year = {2024},
doi = {10.1007/s10840-024-01760-8}
}
EUVIMED